Whilst GATA3 mutations are not yet targetable, synthetic lethal interactions between GATA3 and MDM2 in ER + BC supports pharmacological inhibition of MDM2, shown to significantly impair tumour growth in GATA3-deficient models [36]. This evidence concerns the gene GATA3 and breast cancer.